Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine.
Huhn G, Poorbaugh J, Zhang L, Beasley S, Nirula A, Brothers J, Welbel S, Wilson J, Gillani S, Weber KM, Morack R, Keckler K, Benschop RJ. Huhn G, et al. Among authors: poorbaugh j. PLoS One. 2022 Sep 9;17(9):e0273323. doi: 10.1371/journal.pone.0273323. eCollection 2022. PLoS One. 2022. PMID: 36083883 Free PMC article.
First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19.
Chen P, Datta G, Grace Li Y, Chien J, Price K, Chigutsa E, Brown-Augsburger P, Poorbaugh J, Fill J, Benschop RJ, Rouphael N, Kay A, Mulligan MJ, Saxena A, Fischer WA, Dougan M, Klekotka P, Nirula A, Benson C. Chen P, et al. Among authors: poorbaugh j. Clin Pharmacol Ther. 2021 Dec;110(6):1467-1477. doi: 10.1002/cpt.2405. Epub 2021 Oct 16. Clin Pharmacol Ther. 2021. PMID: 34455583 Free PMC article. Clinical Trial.
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Zhang L, Poorbaugh J, Dougan M, Chen P, Gottlieb RL, Huhn G, Beasley S, Daniels M, Ngoc Vy Trinh T, Crisp M, Freitas JJ, Vaillancourt P, Patel DR, Nirula A, Kallewaard NL, Higgs RE, Benschop RJ. Zhang L, et al. Among authors: poorbaugh j. Front Immunol. 2021 Dec 9;12:790469. doi: 10.3389/fimmu.2021.790469. eCollection 2021. Front Immunol. 2021. PMID: 34956222 Free PMC article. Clinical Trial.
Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab.
Sims JT, Poorbaugh J, Chang CY, Holzer TR, Zhang L, Engle SM, Beasley S, Doman TN, Naughton L, Higgs RE, Kallewaard N, Benschop RJ. Sims JT, et al. Among authors: poorbaugh j. J Transl Med. 2022 Mar 18;20(1):134. doi: 10.1186/s12967-022-03345-3. J Transl Med. 2022. PMID: 35303909 Free PMC article. Clinical Trial.
The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.
Benschop RJ, Tuttle JL, Zhang L, Poorbaugh J, Kallewaard NL, Vaillancourt P, Crisp M, Trinh TNV, Freitas JJ, Beasley S, Daniels M, Haustrup N, Higgs RE, Nirula A, Cohen MS, Marovich M. Benschop RJ, et al. Among authors: poorbaugh j. Sci Transl Med. 2022 Jul 27;14(655):eabn3041. doi: 10.1126/scitranslmed.abn3041. Epub 2022 Jul 27. Sci Transl Med. 2022. PMID: 35679357 Free PMC article. Clinical Trial.
Longitudinal assessment of systemic steroid therapy on hyperinflammatory endothelial biomarker profiles and serology responses of COVID-19 patients.
Sims JT, Chang CY, Poorbaugh J, Daniels M, Beasley SL, Zhang L, Rodgers GH, Lena F, Lacerenza LG, Sposato B, Dupont A, Susen S, Casalini G, Corbellino M, Stebbing J, Krishnan V. Sims JT, et al. Among authors: poorbaugh j. J Transl Med. 2022 Sep 8;20(1):411. doi: 10.1186/s12967-022-03583-5. J Transl Med. 2022. PMID: 36076201 Free PMC article. No abstract available.
Evaluation of plasma IL-21 as a potential biomarker for type 1 diabetes progression.
Schroderus AM, Poorbaugh J, McElyea S, Beasley S, Zhang L, Näntö-Salonen K, Rintamäki R, Pihlajamäki J, Knip M, Veijola R, Toppari J, Ilonen J, Benschop RJ, Kinnunen T. Schroderus AM, et al. Among authors: poorbaugh j. Front Immunol. 2023 Jun 21;14:1157265. doi: 10.3389/fimmu.2023.1157265. eCollection 2023. Front Immunol. 2023. PMID: 37415982 Free PMC article.
Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study.
Datta-Mannan A, Regev A, Coutant DE, Dropsey AJ, Foster J, Jones S, Poorbaugh J, Schmitz C, Wang E, Woodman ME. Datta-Mannan A, et al. Among authors: poorbaugh j. Clin Pharmacol Ther. 2024 May;115(5):1152-1161. doi: 10.1002/cpt.3185. Epub 2024 Jan 31. Clin Pharmacol Ther. 2024. PMID: 38294091 Clinical Trial.
14 results